Plain-English translation of NCT07096869 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is comparing two versions of —a newer version and the established brand-name drug . Researchers want to understand if these two medications work the same way in the body and produce similar results in breast cancer patients.
When a new version of an approved cancer drug becomes available, doctors and patients need to know whether it performs identically to the original. This trial answers that question, which could give patients more treatment options.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive one of the two medications, then after a period of time, you would cross over and receive the other medication. This allows researchers to compare how your body processes each version. You'll need blood tests to check your blood counts, liver function, and kidney function before, during, and after treatment to ensure the medications are being tolerated safely.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Enrollment target
~28 participants
Started
June 2025
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Clinical Trials Information Group officer
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.